Daily versus alternate day dosing of oral Ferrous sulphate in patients of iron deficiency anemia A Randomized open label non inferiority trial - nil

Aiims Raipur0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年6月24日

研究概览

暂无简介。

•1.Age = 16 years
•2.Outpatients with iron deficiency anemia are defined as hemoglobin less than 12.0 g/dL in females or less than 13.0 g/dL in males AND ferritin less than 30 mcg/L

•1.Pregnancy and/or currently breastfeeding
•2.Known history of inflammatory bowel disease, celiac disease, thalassemia or thalassemia trait, and/or inherited bleeding disorder
•3.Known intolerance or lack of response to oral ferrous gluconate, sulfate, or fumarate in the last 12 weeks
•4.Multivitamin and mineral supplements (35 mg or more of elemental iron per day) in 2 weeks prior to randomization
•5.Allergy to oral iron
•6.Allergy to any of the following medicinal and nonmedicinal ingredients in ferrous sulfate: ferrous sulfate, calcium citrate, crospovidone, and talc titanium dioxide
•7.Intravenous iron therapy in the past 12 weeks
•8.On new anticoagulant therapy initiated in the past 6 months (e.g., warfarin, apixaban, dabigatran, rivaroxaban)
•9.Surgery, and/or chemotherapy planned in the upcoming 12 weeks
•10.Previously enrolled in the study
•11.Creatinine clearance less than 30 mL/min
•12.Hemoglobin less than 8.0 g/dL with active bleeding (defined as WHO grade-2 bleeding or higher in the past week
•13.Recent blood donation

发起方

Aiims Raipur